Valladolid

• A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-sm … Ended recruitment
  2023-508359-38-00 5 2024-06-05 Early-stage Non-squamous Non-small Cell Lung Cancer
• Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil … Ended recruitment
  2023-506029-12-00 5 2024-04-03 Migraine
• A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression Ended recruitment
  2023-505268-12-00 5 2024-02-09 Treatment-resistant depression
• A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monothera … Ended recruitment
  2024-512573-27-01 4 2023-12-11 Muscle-invasive bladder cancer (MIBC)
• A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M … Ended recruitment
  2022-501863-41-00 5 2023-11-13 Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
• A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with T … Ended recruitment
  2023-508945-41-00 4 2023-10-11 Hepatocellular Carcinoma
• Study to evaluate reduced antiplatelet therapy after angiolite stent implantation in patients with coronary artery disease Ended recruitment
  2023-507015-35-00 5 2023-10-06 Coronary Artery Disease
• A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) Ended recruitment
  2022-502839-19-00 5 2023-09-14 Obesity
• A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended recruitment
  2022-501176-26-00 5 2023-08-04 Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
• A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis Ended recruitment
  2024-510627-20-00 5 2023-07-28 Non-alcoholic Steatohepatitis (NASH) Cirrhosis
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2) Ended recruitment
  2022-500700-22-00 5 2023-05-25 Active Systemic Lupus Erythematosus (SLE)
• Study of chemotherapy and immunotherapy before and after surgery in patients with non-small cell lung cancer whose tumor is located in the u … Ended recruitment
  2024-512359-19-00 4 2023-05-12 Resectable Non-small cell lung cancer Pancoast tumor
• ETOP 18-21 AMAZE-lung: A clinical study exploring the effect of amivantamab and lazertinib plus bevacizumab treatment, in people diagnosed w … Ended recruitment
  2024-512288-29-00 4 2023-04-11 Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous
• A study to assess safety and efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC) Ended recruitment
  2024-511370-72-00 4 2023-03-29 Primary Sclerosing Cholangitis
• Phase 3 study to evaluate two regimens of ianalumab on top of standardof- care therapy in patients with systemic lupus erythematosus (SIRIUS … Ended recruitment
  2023-508498-97-00 5 2023-02-03 Systemic Lupus Erythematosus
• Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea … Ended recruitment
  2024-514630-21-00 4 2022-08-11 HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Bre
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat … Ended recruitment
  2023-509345-12-00 5 2022-06-22 Multiple Sclerosis
• A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended recruitment
  2023-507131-38-00 5 2022-05-16 Neovascular Age-Related Macular Degeneration (nAMD)
• Efficacy and safety of Frexalimab (SAR441344) in the treatment of Systemic Lupus Erythematosus Ended recruitment
  2023-508654-26-00 4 2022-03-15 Systemic lupus erythematosus
• Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial of therapeutic escalation, the POMEROL tri … Ended recruitment
  2023-508242-18-00 6 2021-12-21 Crohn's disease
• A Study to Evaluate the Efficacy and Safety of BIIB059 (Litifilimab) in Adult Participants With Active Systemic Lupus Erythematosus Receivin … Ended recruitment
  2023-505695-30-00 5 2021-11-30 systemic lupus erythematosus
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• Study of Nivolumab and Ipilimumab plus chemotherapy as a treatment for patients with stage IV lung cancer with brain metastases. Ended recruitment
  2024-513866-20-00 4 2021-11-18 Non-small cell lung cancer with brain metastasis
• A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients … Ended recruitment
  2023-507130-24-00 5 2021-10-22 Neovascular age-related macular degeneration (nAMD)

Showing 97–120 of 182 trials